10.2 G-CSF Dose Modification : For Grade 3 toxicities that are, in 
the judgement of the Principal Investigator, due to G-CSF, the 
dose of G-CSF should be reduced to 50% of the original dose. 
For Grade 4 toxicities that are, in the judgement of the 
Principal Investigator related to G-CSF, the G-CSF should be 
stopped and not resumed. For toxicities of Grade 2 or less that 
are considered by the Principal Investigator to be related to G- 
CSF, an effort should be made to ameliorate the toxicity 
through use of acetaminophen and/or diphenhydramine. If a 
patient cannot tolerate a dose of 5.0 jig/kg G-CSF per day 
during BMT or 2.5jig/Kg during vinblastine treatment, the G- 
CSF will be stopped. 
11.0 On Study Evaluation 
11.1 Daily CBC, platelet count, differential, electrolytes, glucose, 
BUN, creatinine while hospitalized and 2 times per week until 
day 60 post-transplant for patients not receiving vinblastine. 
Patients treated with post-transplant vinblastine will have 
twice weekly CBC . platelet count, and differential performed. 
11.2 Three times per week calcium phosphate, magnesium, albumin, 
total protein, SGOT, SGPT, alkaline phosphatase, LDH, total 
bilirubin, PT, PTT, fibrinogen, TT while hospitalized then 
weekly until day 60 post-transplant. For patients receiving 
vinblastine these studies will be obtained along with 
electrolytes, BUN, creatinine and glucose every 3 weeks. 
11.3 Weekly chest x-ray, urinalysis until hospital discharge. 
1 1 .4 One purple top and one green top tube will be obtained two 
times a week while patients are hospitalized to study the 
presence of the neo- aene marker by PCR. These samples will 
be obtained weekly after hospitalization until Dav 60 post- 
transpiant. These bloods will be ordered bv the study research 
nurse or the clinical associate and transported at room 
temperature to Dr. Ken Cowan's Laboratory. Room 12C110. 
Recombinant DNA Research, Volume 16 
[ 117 ] 
